Charles Atkinson

Array ( [id] => 1212994 [patent_doc_number] => 06710025 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-03-23 [patent_title] => 'Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin' [patent_app_type] => B1 [patent_app_number] => 09/576180 [patent_app_country] => US [patent_app_date] => 2000-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3247 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/710/06710025.pdf [firstpage_image] =>[orig_patent_app_number] => 09576180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1486103 [patent_doc_number] => 06365726 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-04-02 [patent_title] => 'Polynucleotides encoding IL-1 Hy2 polypeptides' [patent_app_type] => B1 [patent_app_number] => 09/578458 [patent_app_country] => US [patent_app_date] => 2000-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 45635 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/365/06365726.pdf [firstpage_image] =>[orig_patent_app_number] => 09578458 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1515482 [patent_doc_number] => 06420544 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-07-16 [patent_title] => 'Polynucleotide and polypeptide sequences encoding murine organic anion transporter 5 (mOATP5)' [patent_app_type] => B1 [patent_app_number] => 09/572147 [patent_app_country] => US [patent_app_date] => 2000-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9876 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/420/06420544.pdf [firstpage_image] =>[orig_patent_app_number] => 09572147 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1202593 [patent_doc_number] => 06720182 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-04-13 [patent_title] => 'Alternative splice variants of CD40' [patent_app_type] => B1 [patent_app_number] => 09/569611 [patent_app_country] => US [patent_app_date] => 2000-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30992 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/720/06720182.pdf [firstpage_image] =>[orig_patent_app_number] => 09569611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1220231 [patent_doc_number] => 06703198 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-03-09 [patent_title] => 'Methods of diagnosing alagille syndrome' [patent_app_type] => B1 [patent_app_number] => 09/566047 [patent_app_country] => US [patent_app_date] => 2000-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 37 [patent_no_of_words] => 33717 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/703/06703198.pdf [firstpage_image] =>[orig_patent_app_number] => 09566047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1602495 [patent_doc_number] => 06432674 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-08-13 [patent_title] => 'Steroid hormone binding protein' [patent_app_type] => B1 [patent_app_number] => 09/565808 [patent_app_country] => US [patent_app_date] => 2000-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 9425 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/432/06432674.pdf [firstpage_image] =>[orig_patent_app_number] => 09565808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1528703 [patent_doc_number] => 06479634 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-11-12 [patent_title] => 'IL-B30 proteins' [patent_app_type] => B1 [patent_app_number] => 09/558089 [patent_app_country] => US [patent_app_date] => 2000-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23314 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/479/06479634.pdf [firstpage_image] =>[orig_patent_app_number] => 09558089 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1440585 [patent_doc_number] => 06495667 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-12-17 [patent_title] => 'Il-b30 antibodies' [patent_app_type] => B1 [patent_app_number] => 09/558087 [patent_app_country] => US [patent_app_date] => 2000-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23622 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/495/06495667.pdf [firstpage_image] =>[orig_patent_app_number] => 09558087 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1448937 [patent_doc_number] => 06455051 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-09-24 [patent_title] => 'Ameliorant for hepatitis C therapeutic effect and application thereof' [patent_app_type] => B1 [patent_app_number] => 09/529303 [patent_app_country] => US [patent_app_date] => 2000-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5187 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/455/06455051.pdf [firstpage_image] =>[orig_patent_app_number] => 09529303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 687166 [patent_doc_number] => 07078493 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2006-07-18 [patent_title] => 'Antibodies to human tumor necrosis factor receptor-like genes' [patent_app_type] => utility [patent_app_number] => 09/526437 [patent_app_country] => US [patent_app_date] => 2000-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 14 [patent_no_of_words] => 71634 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/078/07078493.pdf [firstpage_image] =>[orig_patent_app_number] => 09526437 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1543644 [patent_doc_number] => 06372892 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-04-16 [patent_title] => 'Interleukin1 Hy2 materials and methods' [patent_app_type] => B1 [patent_app_number] => 09/522964 [patent_app_country] => US [patent_app_date] => 2000-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 4 [patent_no_of_words] => 44653 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/372/06372892.pdf [firstpage_image] =>[orig_patent_app_number] => 09522964 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4271711 [patent_doc_number] => 06307024 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-10-23 [patent_title] => 'Cytokine zalpha11 Ligand' [patent_app_type] => 1 [patent_app_number] => 9/522217 [patent_app_country] => US [patent_app_date] => 2000-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 86477 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/307/06307024.pdf [firstpage_image] =>[orig_patent_app_number] => 522217 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 958831 [patent_doc_number] => 06953777 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2005-10-11 [patent_title] => 'Use of interleukin-11 to prevent immune-mediated cytotoxicity' [patent_app_type] => utility [patent_app_number] => 09/521696 [patent_app_country] => US [patent_app_date] => 2000-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 11995 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/953/06953777.pdf [firstpage_image] =>[orig_patent_app_number] => 09521696 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1527456 [patent_doc_number] => 06479049 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-11-12 [patent_title] => 'Methods and compositions for the dry powder formulation of interferons' [patent_app_type] => B1 [patent_app_number] => 09/506426 [patent_app_country] => US [patent_app_date] => 2000-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5432 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/479/06479049.pdf [firstpage_image] =>[orig_patent_app_number] => 09506426 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1550832 [patent_doc_number] => 06399573 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-06-04 [patent_title] => 'Interleukin-1 receptor antagonist beta (IL-1rabeta)' [patent_app_type] => B1 [patent_app_number] => 09/494018 [patent_app_country] => US [patent_app_date] => 2000-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 9332 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/399/06399573.pdf [firstpage_image] =>[orig_patent_app_number] => 09494018 [rel_patent_id] =>[rel_patent_doc_number] =>)